Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease

Galera Therapeutics

MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that it will host a virtual Key Opinion Leader (KOL) event on cisplatin-induced chronic kidney disease on Friday, May 22, 2020, from 10 a.m. to 11 a.m. EDT.

The event will feature a panel discussion regarding the clinical challenges of nephrotoxicity of platinum-based chemotherapy (cisplatin) in the treatment of patients with head and neck cancer, and a summary of the preliminary findings from a retrospective analysis of Phase 2b trial data in patients with head and neck cancer and the potential role of avasopasem manganese (GC4419) in this patient population.

The live audio webcast of the event will be accessible from the Investors page of Galera’s website, Individuals can participate in an interactive Q&A by submitting questions via the webcast platform.

READ:  HHS Announces Phase Two of HPV Vaccination Campaign for Young Adults

An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 60 days following the event.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.